TransCelerate to Lead AI, Real-World Evidence Discussions at PHUSE US Connect 2026
Event summary
- TransCelerate BioPharma will deliver two keynotes and participate in multiple panel sessions at PHUSE US Connect 2026, held March 22–26 in Austin, Texas.
- Lilliam Rosario, Ph.D., and Rob DiCicco will discuss AI-enabled translational safety, real-world evidence integration, and clinical enterprise modernization.
- Rosario’s keynote will focus on patient-centered innovation and regulatory confidence, while DiCicco will examine evidence generation challenges under the Twenty-First Century Cures Act.
- Panel discussions will cover AI-driven transformation, real-world evidence strategies, and interoperability standards.
The big picture
TransCelerate’s active role at PHUSE US Connect 2026 underscores the growing importance of AI and real-world evidence in modernizing clinical trials. The organization’s focus on cross-industry collaboration aligns with broader industry trends toward data-driven development and regulatory efficiency. As biopharmaceutical companies increasingly leverage digital health technologies, the ability to integrate diverse data sources will be critical for accelerating evidence generation and improving patient outcomes.
What we're watching
- AI Integration
- How TransCelerate’s AI-driven initiatives will impact translational safety and regulatory confidence.
- Regulatory Alignment
- Whether the industry can fully realize the promise of the Twenty-First Century Cures Act through real-world evidence.
- Cross-Industry Collaboration
- The pace at which standards organizations advance interoperability across research and care.
Our editorial coverage: